By Sophie Lindqvist

Nigeria, Barbados and Afreximbank have advanced plans for a $32 million intravenous (IV) fluids plant in Barbados, but its 2029 production target remains conditional. Initial annual capacity would reach 12 million units, with room for expansion; construction has not started and final financing remains outstanding.

The parties signed agreements on the sidelines of the 2026 Commonwealth Heads of Government Meeting (CHOGM) in St John’s, Antigua and Barbuda. The partnership comprises the governments of Nigeria and Barbados, Barbados Pharmaceutical Inc. (BPI), Nigerian manufacturer AMA Medical Manufacturing and the African Export-Import Bank (Afreximbank).

The stated case rests on stronger medicine production, regional health security and more trade between Africa and the Caribbean. If completed, the factory would give the Caribbean a domestic source of IV fluids, essential products used across healthcare systems. It could reduce import dependence, but no plant output exists and broader pharmaceutical self-sufficiency remains unproven.

What does this change for Caribbean healthcare?

The immediate gain is contractual rather than operational. BPI and AMA signed a memorandum of understanding (MOU), a statement of shared intent, while AMA and Afreximbank signed a preliminary term sheet for a Project Preparation Facility (PPF), an early-stage financing arrangement. The PPF term sheet marks only the first step toward a comprehensive financing arrangement.

The proposed financing blueprint would combine project preparation support with three further capital layers. None should be treated as secured funding until the parties complete the wider financing process.

Senior Executive Vice-President Denys Denya said: “Our intention is to provide a comprehensive financing solution, beginning with the Project Preparation Facility and extending to senior debt, working capital and risk-bearing instruments.” He described an intention, not the completed financing package.

The proposed capital structure comprises:

• Project preparation support: funding for early-stage development.
• Senior debt: borrowings that rank ahead of junior claims.
• Working capital: cash for routine operating needs.
• Risk-bearing instruments: financing that shares or absorbs project risk.

Barbados Prime Minister Mia Amor Mottley linked the agreements to economic resilience and practical cooperation between Africa and the Caribbean. She said Barbados’ ambitions for its people and the region were not constrained by the state’s size. She said the partnership would build productive capacity, strengthen health security and create opportunities for future generations, although those objectives still depend on execution.

Nigeria’s Secretary to the Government of the Federation, Senator George Akume, said the partnership reflected a commitment to deepen economic cooperation through practical industrial initiatives. He said combining Nigerian manufacturing expertise with Caribbean investment opportunities would strengthen healthcare production, expand trade, and support technology exchange and skills development, though those gains remain contingent on a viable factory.

World Trade Organisation (WTO) Director-General Dr Ngozi Okonjo-Iweala welcomed the initiative as trade and investment driving South-South cooperation, meaning exchanges between developing countries. She said it could diversify pharmaceutical supply chains, connect African and Caribbean industrial capabilities and create economic-development opportunities.

Okonjo-Iweala said: “We are delighted to see this partnership taking shape, and to have been part of the journey. This is re-globalization in action.” She recalled that COVID-19 exposed the risks of concentrating essential medical production in a limited number of countries, a concentration the project aims to reduce.

Denya said the initiative extends Afreximbank’s growing Caribbean partnership, which gained momentum during COVID-19 through efforts to facilitate vaccine access. He said the factory would support local production of essential medicines, stronger health sovereignty, meaning national control over medicine supply, technology transfer and skilled employment. Those benefits depend on the facility operating.

AMA Holdings Chairman Abdullahi Musa Bello said the arrangement would introduce the Nigerian company’s manufacturing capabilities to a new market and contribute to Caribbean pharmaceutical development. He said the operation’s focus would be commercial viability, supported by technical expertise, reliable supply chains and sustainable market opportunities.

BPI Acting Chief Executive Officer Dr Cindi Lewis called conversion of the agreements into a functioning manufacturing operation the immediate priority. That remains the central execution risk: political agreement has preceded proof of commercial, regulatory and construction readiness.

Before production, the project must clear four sequential gates. Passing one does not remove the conditions attached to the next.

• Feasibility assessments.
• Project preparation and comprehensive financing.
• Regulatory approvals.
• Construction processes.

Barbados enacted legislation in June 2026 to establish the Barbados Medical Products Authority. Its regulatory and institutional implementation remains underway, leaving the approval system itself a work in progress.

There is already a limited trade track record: AMA’s first shipment of IV fluids reached Barbados in March 2026. AMA plans further shipments for Antigua and Barbuda, the British Virgin Islands and St Lucia. These shipments show the distribution route is functioning, but they do not establish factory-scale output.

BPI is also working with AMA-MED and Barbados-based Lenstec to explore opportunities for Barbadian medical technology in Nigeria. The initiative remains exploratory, rather than an agreed commercial rollout.

The facility is intended as a foundation for broader pharmaceutical industrial development, including skills development, regulatory capacity, investment and market access. What this changes for the Caribbean is the possibility of local IV-fluid capacity and greater supply-chain resilience; what it delivers is less certain until feasibility, binding finance, permits and construction are complete.